Physician profile
Patrick Martin Cooney
NPI 1811527682
$90,568.70
in general payments reported to CMS, 2019-2025
38 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,233 · 2022: $2,951 · 2023: $15K · 2024: $35K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $22K · Honoraria: $9,250 · Travel and Lodging: $7,335 · Consulting Fee: $7,250 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,226.00 |
| Food and Beverage | $22,102.69 |
| Honoraria | $9,250.00 |
| Travel and Lodging | $7,334.54 |
| Consulting Fee | $7,250.00 |
| Education | $220.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,071.70 | 2021-2025 | |
| Axsome Therapeutics, INC. | $20,753.33 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $18,362.29 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,749.22 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,562.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $2,271.77 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Neurocrine Biosciences, INC. | $1,871.00 | 2021-2025 | Ingrezza |
| Corium, LLC | $1,560.64 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $1,075.45 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,014.36 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Tris Pharma INC | $906.58 | 2022-2025 | Dyanavel Xr |
| Lundbeck LLC | $861.76 | 2021-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $659.29 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $556.80 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $510.84 | 2022-2025 | Qelbree, Qelbree |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $405.86 | 2024-2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $348.25 | 2025 | Jornay Pm |
| Validus Pharmaceuticals LLC | $322.52 | 2023-2025 | Raldesy, Equetro, Equetro |
| E.R. Squibb & Sons, L.L.C. | $276.62 | 2025 | Cobenfy |
| Almatica Pharma LLC | $275.47 | 2023-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $272.11 | 2021-2022 | |
| Bausch Health US, LLC | $265.36 | 2021-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $257.34 | 2024 | |
| Novo Nordisk INC | $210.03 | 2024-2025 | Wegovy |
| Avanir Pharmaceuticals, INC. | $190.68 | 2021-2022 | |
| Neos Therapeutics, Lp | $160.15 | 2024-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $115.18 | 2022-2023 | Belsomra |
| Indivior INC. | $101.05 | 2023-2024 | Sublocade |
| Luye Pharma (USA) Ltd. | $94.34 | 2025 | Erzofri Extended-Release |
| Lilly USA, LLC | $81.50 | 2025 | Mounjaro, Zepbound |
| Eisai INC. | $77.16 | 2021 | |
| Bioxcel Therapeutics, INC. | $72.80 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $62.83 | 2021 | |
| Noven Therapeutics, LLC | $61.48 | 2024 | Xelstrym |
| Owp Pharmaceuticals, INC. | $53.24 | 2024-2025 | Subvenite |
| Adlon Therapeutics L.P. | $41.60 | 2021 | |
| Janssen Biotech, INC. | $22.19 | 2023 | |
| Neuronetics, INC. | $13.35 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.